Our observations that WNF does not interfere with the amyloidogenic β-secretase activity but significantly lowers both Aβ40 and Aβ42 production underline the fact that any therapeutic strategy leading to α-secretase activation with no modification of β-secretase activity is expected to be sufficient to impair Aβ generation and is in good agreement with the observation that the sole ADAM10 overexpression reduces both Aβ40 and Aβ42 levels in vivo in the brain of a transgenic mouse model of AD [27]. Here, ADAM10 is linked to Alzheimer disease.